We were able to detect some indication of possible associations of genetic variability in IL1β with the risk for PD or NOS1, SOD2, IL1β, and CAT with certain non-motor AEs of dopaminergic replacement therapy; however, the evidence presented here is limited. This evidence concerns the gene IL1B and Parkinson disease.